Three Top Ways to Trade the Spread of Mpox
The World Health Organization (WHO) just declared Mpox a global public health emergency for the second time following an outbreak in the Democratic Republic of Congo to other countries.
As noted by WHO:
WHO Director-General Dr Tedros Adhanom Ghebreyesus has determined that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC) under the International Health Regulations (2005) (IHR).
In declaring the PHEIC, Dr Tedros said, “The emergence of a new clade of mpox, its rapid spread in eastern DRC, and the reporting of cases in several neighbouring countries are very worrying. On top of outbreaks of other mpox clades in DRC and other countries in Africa, it’s clear that a coordinated international response is needed to stop these outbreaks and save lives.”
That being said, investors may want to jump into Mpox testing and treatment stocks, such as:
Emergent BioSolutions (SYM: EBS)
Emergent BioSolutions (EBS) could push even higher after the US FDA approved the company’s smallpox vaccine for Mpox. “This expanded indication for ACAM2000 comes at a critical time as the global health community comes together to ensure an effective and cohesive response to the recent upsurge in Mpox cases,” said Emergent CEO Joe Papa in a press release.
Virax Biolabs (SYM: VRAX)
VRAX just signed a distribution pact for Mpox diagnostic kits in Europe and the Middle East.
“The RT PCR Mpox virus detection kits are approved for sale in Europe and also authorized by the Medicines and Healthcare Products Regulatory Agency, the product regulatory agency for the United Kingdom. These tests perform with a sensitivity of 96.7% and specificity of 93.72%, with the ability to deliver results in under 70 minutes,” as noted by Benzinga.
Applied DNA Sciences (SYM: APDN)
APDN just announced that its clinical laboratory subsidiary, Applied DNA Clinical Labs, submitted a validation package to the New York State Department of Health in support of an expansion of the permitted use of its Linea Mpox Virus 1.0 Assay to include both mpox clade I and clade II, as noted in a company press release.
